Researchers at Zhejiang University have successfully engineered yeast to produce vinblastine, a potent chemotherapy medication. Historically, the drug has been harvested exclusively from the Madagascar periwinkle plant, a process that is both labor-intensive and inefficient. According to the research team, it previously required two tonnes of dried periwinkle leaves to produce a single gram of the drug, which contributed to its high cost and supply volatility.

By modifying the molecular structure of yeast, the team has created a biological "factory" capable of synthesizing the drug at a rate 1,000 times faster than natural extraction. This breakthrough aims to address the global scarcity of vinblastine, which is essential for treating various forms of cancer, including lymphoma and testicular cancer. While the study highlights a significant leap in pharmaceutical manufacturing, the report notes that the drug's current market price is higher than gold by weight due to the difficulty of sourcing it from the periwinkle plant. The researchers suggest that this synthetic biology approach could stabilize the supply chain and potentially lower costs for patients in the future. The findings represent a major shift in how complex plant-based compounds are manufactured, moving away from traditional agricultural reliance toward scalable laboratory production.